BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The...

Published on 25 Nov 2024 on Simply Wall St. · via Yahoo Finance

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is possibly approaching a major achievement in its...

Read the rest of the article

Start tracking your investments with Statfolio

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, ...

Simply Wall St. · via Yahoo Finance 27 Dec 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is possibly approaching a major achievement in its...

Simply Wall St. · via Yahoo Finance 25 Nov 2024

Total Revenue: $117.1 million for the quarter. ORLADEYO Revenue: $116.3 million, nearly 36%...

GuruFocus.com · via Yahoo Finance 5 Nov 2024

We recently made a list of Piper Sandler’s Top Technical Stock Picks: 20 Best Stocks. In this pie...

Insider Monkey · via Yahoo Finance 13 Oct 2024

We recently published a list of 10 Best Biotech Stocks To Buy Under $20. In this article, we are ...

Insider Monkey · via Yahoo Finance 6 Oct 2024

Key Insights BioCryst Pharmaceuticals' Annual General Meeting to take place on 12th of JuneSalary...

Simply Wall St. · via Yahoo Finance 18 Jun 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is possibly approaching a major achievement in its b...

Simply Wall St. via Yahoo Finance 29 May 2024

Anthony Doyle, Chief Financial Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 3...

GuruFocus.com via Yahoo Finance 15 May 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) defied analyst predictions to release its first-quar...

Simply Wall St. via Yahoo Finance 9 May 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript May 6, 2024 BioCrys...

Insider Monkey via Yahoo Finance 7 May 2024